Dihidreksidin (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Dihidreksidin" in Serbian language version.

refsWebsite

Global rank Serbian rank

11nih.gov

4^th place

8^th place

2archive.org

6^th place

5^th place

1doi.org

2^nd place

4^th place

archive.org

George MS, Molnar CE, Grenesko EL, Anderson B, Mu Q, Johnson K, Nahas Z, Knable M, Fernandes P, Juncos J, Huang X, Nichols DE, Mailman RB (2007). „A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia.”. Schizophr Res. 93 (1-3): 42—50. PMID 17467956.
Mu Q, Johnson K, Morgan PS, Grenesko EL, Molnar CE, Anderson B, Nahas Z, Kozel FA, Kose S, Knable M, Fernandes P, Nichols DE, Mailman RB, George MS (2007). „A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia.”. Schizophr Res. 94 (1-3): 332—341. PMID 17596915.

doi.org

Zhang J, Xiong B, Zhen X, Zhang A (2009). „Dopamine D1 receptor ligands: where are we now and where are we going.”. Med Res Rev. 29 (2): 272—294. PMID 18642350. doi:10.1002/med.20130.

nih.gov

ncbi.nlm.nih.gov

Lovenberg TW, Brewster WK, Mottola DM, Lee RC, Riggs RM, Nichols DE, Lewis MH, Mailman RB (1989). „Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist.”. Eur J Pharmacol. 166 (1): 111—113. PMID 2572425.
Mottola DM, Brewster WK, Cook LL, Nichols DE, Mailman RB (1992). „Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist.”. J Pharmacol Exp Ther. 262 (1): 383—393. PMID 1352553.
Darney KJ Jr; Lewis MH; Brewster WK; Nichols DE; Mailman RB. (1991). „Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist.”. Neuropsychopharmacology. 5 (3): 187—195. PMID 1684499.
Taylor JR, Lawrence MS, Redmond DE Jr, Elsworth JD, Roth RH, Nichols DE, Mailman RB (1991). „Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys.”. Eur J Pharmacol. 199 (3): 389—391. PMID 1680717.
Mailman RB, Nichols DE (1998). „Dopamine D1 receptor agonists as antiparkinson drugs.”. Trends Pharmacol Sci. 19 (7): 255—256. PMID 9703756.
Blanchet PJ, Fang J, Gillespie M, Sabounjian L, Locke KW, Gammans R, Mouradian MM, Chase TN (1998). „Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease.”. Clin Neuropharmacol. 21 (6): 339—343. PMID 9844789.
George MS, Molnar CE, Grenesko EL, Anderson B, Mu Q, Johnson K, Nahas Z, Knable M, Fernandes P, Juncos J, Huang X, Nichols DE, Mailman RB (2007). „A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia.”. Schizophr Res. 93 (1-3): 42—50. PMID 17467956.
Mu Q, Johnson K, Morgan PS, Grenesko EL, Molnar CE, Anderson B, Nahas Z, Kozel FA, Kose S, Knable M, Fernandes P, Nichols DE, Mailman RB, George MS (2007). „A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia.”. Schizophr Res. 94 (1-3): 332—341. PMID 17596915.
Mailman R, Huang X, Nichols DE (2001). „Parkinson's disease and D1 dopamine receptors.”. Curr Opin Investig Drugs. 2 (11): 1582—1591. PMID 11763161.
Salmi P, Isacson R, Kull B (2004). „Dihydrexidine--the first full dopamine D1 receptor agonist.”. CNS Drug Rev. 10 (3): 230—242. PMID 15492773.
Zhang J, Xiong B, Zhen X, Zhang A (2009). „Dopamine D1 receptor ligands: where are we now and where are we going.”. Med Res Rev. 29 (2): 272—294. PMID 18642350. doi:10.1002/med.20130.